All In Biotech

NDA 217836 · Orasis Pharms

Qlosi

Pilocarpine Hydrochloride · Ophthalmic

Last checked: Nov 19, 2026Latest source record: Oct 17, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Oct 17, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

57

21 Phase 3, 2 recruiting

FAERS reports

1,260

645 serious, 34 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 10, 2026.

QLOSI is indicated for the treatment of presbyopia in adults. QLOSI is a cholinergic agonist indicated for the treatment of presbyopia in adults. ( 1 )

Mechanism: Pilocarpine hydrochloride is a cholinergic muscarinic agonist which activates muscarinic receptors located at smooth muscles such as the iris sphincter muscle and ciliary muscle. QLOSI contracts the iris sphincter muscle, constricting the pupil to enhance the depth of focus and improve near visual acuity while maintaining some pupillary response to light.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • QLOSI · PILOCARPINE HYDROCHLORIDE 0.4% · SOLUTION/DROPS, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pilocarpine" as an intervention, any sponsor and status, largest first.

All 57 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective143
  • headache104
  • fatigue97
  • pain96
  • eye pain91
  • dyspnoea85
  • nausea80
  • dizziness76
  • diarrhoea74
  • off label use70
  • cough68
  • fall67

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200417
200520
20066
20075
200815
200935
201043
20118
201214
201318
201415
201516
20167
201729
201840
201977
202093
202168
2022119
2023107
2024140
2025216
2026152

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 408 on PubMed

Sponsor: Orasis Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.